IS CISPLATINUM VESTIBULOTOXIC

Serial vestibular testing was performed on 34 patients undergoing cis- platinum chemotherapy and 12 age-matched normal subjects. Vestibular t esting comprised caloric and low-frequency, sinusoidal rotational test ing (0.01 to 0.16 Hz). Test-retest variability in the caloric and rota tional vestibular assessment of the normal subjects formed the basis f or evaluation of subclinical loss of vestibular function within our pa tient population. In spite of high-dose cis-platinum chemotherapy (100 mg/m2) with cumulative dosages to 1600 mg, no clear evidence of vesti bular toxicity was found.